Our research program aims to elucidate the molecular function of DNA modifications in normal cells and cancer. We employ biochemistry and in vivo approaches to investigate roles of DNA modifications in transcription, heritability, mutability and nuclear organisation. Together with advancing knowledge of the basic biology of DNA, we delineate defects in cancer and aim to target them for the therapy.
Until recently, methylation of cytosine (5-methylcytosine, 5mC) was the only recognized DNA modification present in mammalian DNA. We and others have demonstrated the existence of 5-hydroxymethylcytosine (5hmC), which is a product of TET family of oxygenases acting on methylated cytosine. In cycling cells, 5hmC is a demethylation intermediate, but it is found as a long-lived base in post-mitotic cells, where its function is less well understood.
An example of our recent work is an investigation of the hypothesis that stable 5hmC may have an impact on the mutability of DNA, since 5mC is known to relate to increased C-to-T transitions. By employing computational analysis relating 5hmC localisation in normal human tissues with mutational frequencies in cancer, we demonstrated that 5hmCs have lower mutation frequency than 5mCs.
While 5hmC in the DNA carry a benefit of reduce mutability, its presence in the nucleotide pool (used to synthesize new strands of DNA) is mutagenic. 5hmC and other biologically modified bases can enter nucleotide pool via recycling of epigenetically modified DNA. Our research on the metabolism of epigenetic nucleotides demonstrated that cytidine monophosphate kinase 1 (CMPK1) restricts production of 5hmdCTP and prevents incorporation of the modified base directly into DNA. However, cytidine deaminase (CDA) deaminates 5hmdC resulting 5hmdU, which is phosphorylated and incorporated into DNA, causing DNA damage. We are currently exploring whether this phenomenon can be exploited for personalised cancer therapy, targeting tumours overexpressing CDA.
A critique of the hypothesis that CA repeats are primary targets of neuronal MeCP2.
Chhatbar K. et al, (2022), Life science alliance, 5
Decitabine increases neoantigen and cancer testis antigen expression to enhance T cell-mediated toxicity against glioblastoma.
Ma R. et al, (2022), Neuro-oncology
Repressed Chromatin Drives Leukaemogenesis in Mutant IDH2 Acute Myeloid Leukaemia Via Inhibition of Granulocyte Differentiation and Cell Cycle Progression
Silveira DRA. et al, (2021), BLOOD, 138
ELEVATED 2HG DOES NOT CAUSE FEATURES OF TUMORIGENESIS
Adam J. et al, (2021), NEURO-ONCOLOGY, 23, 1 - 1
LKB1 cooperates with Sox17 to drive metastasis.
Kriaucionis S., (2021), Nature cell biology, 23, 816 - 817